The other thing that burns me up is the fact they have a potential cancer treatment. There are cancer patients who could benefit from Prolanta if its effective. Making them wait for a treatment because you want to focus on ticker changes and uplists just doesn't seem right. Getting through the trials and potentially helping people has to be first on the list.
To be fair, the new Symbol, otcQB etc was fine to get done. That didnt slow down the recruitment process at all.
The real concern is the secrecy surrounding the clinicals which apparently began recruitment back in Jan.
Now, the restructuring of debt was necessary but should not be misconstrued as a vote of confidence for Oncolix. The 2017 note holding vultures had little choice but to cough up some more $$ or lose it all.
News 
Market Data 
Discover 
AI
